Xeroderma Pigmentosum (Kaposi's Disease)

A rare, pigmentary, and atrophic autosomal recessive disease. It is manifested as an extreme photosensitivity to ULTRAVIOLET RAYS as the result of a deficiency in the enzyme that permits excisional repair of ultraviolet-damaged DNA.
Also Known As:
Kaposi's Disease; Kaposis Disease; Kaposi Disease
Networked: 1684 relevant articles (23 outcomes, 85 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Skin Neoplasms (Skin Cancer)
2. Neoplasms (Cancer)
3. Basal Cell Nevus Syndrome (Gorlin Syndrome)
4. Head and Neck Neoplasms (Head and Neck Cancer)
5. Squamous Cell Carcinoma (Epidermoid Carcinoma)


1. Sarasin, Alain: 22 articles (05/2009 - 01/2002)
2. Hanaoka, Fumio: 20 articles (05/2015 - 01/2002)
3. Kraemer, Kenneth H: 20 articles (04/2015 - 06/2002)
4. Lehmann, Alan R: 17 articles (02/2015 - 01/2002)
5. Khan, Sikandar G: 15 articles (04/2015 - 06/2002)
6. Masutani, Chikahide: 14 articles (05/2015 - 01/2002)
7. Tanaka, Kiyoji: 12 articles (08/2015 - 04/2002)
8. Egly, Jean-Marc: 11 articles (02/2015 - 06/2003)
9. Cleaver, James E: 11 articles (07/2014 - 01/2002)
10. Mori, Toshio: 10 articles (07/2014 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Xeroderma Pigmentosum:
1. Isotretinoin (Accutane)FDA LinkGeneric
2. DNA (Deoxyribonucleic Acid)IBA
3. DNA AdductsIBA
4. RetinoidsIBA
5. AcitretinFDA Link
6. Codon (Codons)IBA
7. PlatinumIBA
10/01/2013 - "Our previous studies have demonstrated the involvement of xeroderma pigmentosum group A (XPA) codon23 and xeroderma pigmentosum group D (XPD) codon751 single-nucleotide polymorphisms (SNPs) in clinical response to platinum based chemotherapy in advanced NSCLC patients. "
05/01/2009 - "We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. "
09/22/2015 - "The current study aims to test the hypothesis that eIF3a may affect the drug response and prognosis of ovarian cancer patients receiving platinum-based chemotherapy by regulating xeroderma pigmentosum complementation group C (XPC) and p27(Kip1). "
03/01/2012 - "The aim of this study was to investigate whe- ther X-ray repair cross-complementing group 3 (XRCC3) and xeroderma pigmentosum group D (XPD) single nucleotide polymorphism (SNP) affects the outcome of platinum- based chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients. "
01/01/2015 - "We conducted a cohort study to investigate whether 3 potential single nucleotide polymorphisms (SNPs) in the xeroderma pigmentosum complementation group G (XPG) gene could predict the survival of advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based doublet chemotherapy. "
8. Bleomycin (Blenoxane)FDA LinkGeneric
9. 4-Nitroquinoline-1-oxide (4 Nitroquinoline 1 oxide)IBA
10. EtretinateFDA Link

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Chemoprevention
3. Bone Marrow Transplantation (Transplantation, Bone Marrow)
4. Transplants (Transplant)
5. Oral Administration